European Prevention of Alzheimer’s Dementia (EPAD)
The European Prevention of Alzheimer’s Dementia (EPAD) consortium is one of the largest public-private partnerships in the history of AD research. In 2016, EPAD began a longitudinal cohort study that screened more than 2,000 participants to collect a wide range of cognitive, clinical, neuroimaging and biomarker data to help further our understanding of the early stages of Alzheimer’s disease. From these 2,000 participants EPAD followed up with 1,225 after one year, 421 after two years and 121 after three yearsbefore funding from the Innovative Medicine Initiative (IMI) ceased. Several national initiatives are in development to ensure long-term follow-up on all EPAD participants across Europe.
The current EPAD database, provided by Aridhia, is open-access, ensuring the use of the data for the Alzheimer’s disease research community worldwide. Data access is free to all researchers.ACCESS AND DATA
The EPAD LCS Research Access Process (ERAP) was set up and designed to give academic researchers and institutions and companies from all over the world a simple, quick way to access the data collected during the longitudinal cohort study.
Three databases have been released:
- EPAD LCS V500.0, which includes data from the first 500 people to enter the cohort;
-  EPAD LCS V1500.0, which includes data from the first 1,500 people to enter the cohort; and
-  EPAD LCS V500.1, which includes updated data from the first 500 participants, including one-year follow-up data.
A fourth dataset yet to be released includes all complete data up to the date the study was halted due to Covid-19 and the subsequent end of the IMI grant. The database contains cognitive (e.g. RBANS, MMSE, CDR), clinical (e.g. medical history, medications), biomarker (APOE, [CSF] Aβ42, tau), and neuroimaging and lifestyle risk factor (sleep, diet, traumatic life events) data sets reflecting participants with a range of disease severities from normal aging to prodromal Alzheimer’s dementia. Moreover, a very large BioBank is available for sample access that includes CSF, blood and saliva from all participant visits.
The catalogue of available data and samples for researchers and the process for accessing them will be presented in detail on the EPAD website in October 2020. At that time, full quality control will be completed for all the EPAD collected data and samples.
New data collection from emerging national studies will be incorporated into the AD Workbench to provide even greater value to the global neuroscience research community.